Gallbladder Cancer Questions & Answers

1. Key statistics for gallbladder cancer. American Cancer Society. Available at https://www.cancer.org/cancer/gallbladder-cancer/about/key-statistics.html. January 12, 2023; Accessed: September 27, 2023.

2. Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022 Oct 27. 8 (1):69. [QxMD MEDLINE Link].

3. Oh D-Y, et al; TOPAZ-1 Investigators. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. June 1, 2022. 1(8):[Full Text].

4. Woods E, Le D, Jakka BK, Manne A. Changing Landscape of Systemic Therapy in Biliary Tract Cancer. Cancers (Basel). 2022 Apr 25. 14 (9):[QxMD MEDLINE Link]. [Full Text].

5. Shaffer EA. Gallbladder cancer: the basics. Gastroenterol Hepatol (N Y). 2008 Oct. 4 (10):737-41. [QxMD MEDLINE Link]. [Full Text].

6. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014. 6:99-109. [QxMD MEDLINE Link]. [Full Text].

7. Schottenfeld D and Fraumeni J. Cancer. Epidemiology and Prevention. 3rd. Oxford University Press; 2006. 787-800.

8. Lowenfels AB, Maisonneuve P, Boyle P, Zatonski WA. Epidemiology of gallbladder cancer. Hepatogastroenterology. 1999 May-Jun. 46(27):1529-32. [QxMD MEDLINE Link].

9. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001 Feb 15. 91(4):854-62. [QxMD MEDLINE Link].

10. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006 Apr 1. 118(7):1591-602. [QxMD MEDLINE Link].

11. Matsukura N, Yokomuro S, Yamada S, Tajiri T, Sundo T, Hadama T, et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res. 2002 Jul. 93(7):842-7. [QxMD MEDLINE Link].

12. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24. 348(17):1625-38. [QxMD MEDLINE Link].

13. Tsuchiya Y, Sato T, Kiyohara C, Yoshida K, Ogoshi K, Nakamura K. Genetic polymorphisms of cytochrome P450 1A1 and risk of gallbladder cancer. J Exp Clin Cancer Res. 2002 Mar. 21(1):119-24. [QxMD MEDLINE Link].

14. Singh MK, Pandey UB, Ghoshal UC, Srivenu I, Kapoor VK, Choudhuri G. Apolipoprotein B-100 XbaI gene polymorphism in gallbladder cancer. Hum Genet. 2004 Feb. 114(3):280-3. [QxMD MEDLINE Link].

15. Mhatre S, Wang Z, Nagrani R, Badwe R, Chiplunkar S, Mittal B, et al. Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study. Lancet Oncol. 2017 Apr. 18 (4):535-544. [QxMD MEDLINE Link].

16. Wu LC, Chen LT, Tsai YJ, Lin CM, Lin CY, Tian YF, et al. Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator. J Clin Pathol. 2012 Apr. 65(4):309-14. [QxMD MEDLINE Link].

17. Benjamin IS. Biliary cystic disease: the risk of cancer. J Hepatobiliary Pancreat Surg. 2003. 10(5):335-9. [QxMD MEDLINE Link].

18. Hu B, Gong B, Zhou DY. Association of anomalous pancreaticobiliary ductal junction with gallbladder carcinoma in Chinese patients: an ERCP study. Gastrointest Endosc. 2003 Apr. 57(4):541-5. [QxMD MEDLINE Link].

19. Rahman R, Simoes EJ, Schmaltz C, Jackson CS, Ibdah JA. Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study. Cancer Med. 2017 Apr. 6 (4):874-880. [QxMD MEDLINE Link]. [Full Text].

20. American Joint Committee on Cancer. Gallbladder. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, et al, eds. AJCC Cancer Staging Manual. 8th Edition. New York: Springer; 2016.

21. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004 Mar. 11(3):310-5. [QxMD MEDLINE Link].

22. Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, et al. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imaging. 2018 Apr 14. 50:223-228. [QxMD MEDLINE Link].

23. You MW, Yun SJ. Diagnostic performance of diffusion-weighted imaging for differentiating benign and malignant gallbladder lesions: A systematic review and meta-analysis. J Magn Reson Imaging. 2018 Apr 20. [QxMD MEDLINE Link].

24. Mohandas KM, Swaroop VS, Gullar SU, Dave UR, Jagannath P, DeSouza LJ. Diagnosis of malignant obstructive jaundice by bile cytology: results improved by dilating the bile duct strictures. Gastrointest Endosc. 1994 Mar-Apr. 40(2 Pt 1):150-4. [QxMD MEDLINE Link].

25. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers. NCCN. Available at https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf. Version 2.2023 — May 10, 2023; Accessed: September 27, 2023.

26. [Guideline] Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Feb. 34 (2):127-140. [QxMD MEDLINE Link]. [Full Text].

27. Hyder O, Dodson RM, Sachs T, Weiss M, Mayo SC, Choti MA, et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score-matched Surveillance, Epidemiology, and End Results analysis. Surgery. 2013 Jul 19. [QxMD MEDLINE Link].

28. Lamarca A, et al; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 May. 22 (5):690-701. [QxMD MEDLINE Link]. [Full Text].

29. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8. 362 (14):1273-81. [QxMD MEDLINE Link]. [Full Text].

30. Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010 Oct 20. 28(30):4581-6. [QxMD MEDLINE Link].

31. Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver Int. 2023 Aug. 43 (8):1803-1812. [QxMD MEDLINE Link].

32. Malka D, et al; BINGO investigators. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014 Jul. 15 (8):819-28. [QxMD MEDLINE Link]. [Full Text].

33. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1. 5 (6):824-830. [QxMD MEDLINE Link]. [Full Text].

34. Iqbal S, Rankin C, Lenz HJ, et al. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec. 68(6):1595-602. [QxMD MEDLINE Link].

35. Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020 Oct 7. 5 (1):230. [QxMD MEDLINE Link]. [Full Text].

36. Gallardo J, Rubio B, Ahumada M, et al. Therapy for advanced gallbladder cancer: Improving survival. J Clin Oncol. 2008 (May 20 suppl; abstr 15566). 26:[Full Text].

37. Dixon E, Vollmer CM Jr, Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005 Mar. 241(3):385-94. [QxMD MEDLINE Link]. [Full Text].

38. Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg. 2011 Aug. 254(2):320-5. [QxMD MEDLINE Link].

39. Okumura K, Gogna S, Gachabayov M, Felsenreich DM, McGuirk M, Rojas A, et al. Gallbladder cancer: Historical treatment and new management options. World J Gastrointest Oncol. 2021 Oct 15. 13 (10):1317-1335. [QxMD MEDLINE Link]. [Full Text].

40. Jensen EH, Abraham A, Jarosek S, Habermann EB, Al-Refaie WB, Vickers SA, et al. Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery. 2009 Oct. 146(4):706-11; discussion 711-3. [QxMD MEDLINE Link].

41. Anderson MA, Appalaneni V, Ben-Menachem T, Decker GA, Early DS, Evans JA, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc. 2013 Feb. 77 (2):167-74. [QxMD MEDLINE Link].

42. Ahn S, Lee JC, Shin DW, Kim J, Hwang JH. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020 Jul 23. 10 (1):12348. [QxMD MEDLINE Link]. [Full Text].

Eric Fox, DO, MA Fellow in Hematology/Oncology, Main Line Health, Lankenau Medical Center

Eric Fox, DO, MA is a member of the following medical societies: American College of Physicians, American Society of Clinical Oncology, American Society of Hematology

Disclosure: Nothing to disclose.

Andrew S Kennedy, MD, FACRO Physician-in-Chief, Radiation Oncology, Sarah Cannon; Director, Radiation Oncology Research, Sarah Cannon Research Institute

Andrew S Kennedy, MD, FACRO is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American Society for Radiation Oncology, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Radiological Society of North America

Disclosure: Nothing to disclose.

Jessica Katz, MD, PhD Senior Medical Director, Hematology, Global Drug Development, Bristol Myers Squibb

Jessica Katz, MD, PhD is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology

Disclosure: Employee of Bristol Myers Squibb.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Benjamin Movsas, MD

Benjamin Movsas, MD is a member of the following medical societies: American College of Radiology, American Radium Society, American Society for Radiation Oncology

Disclosure: Nothing to disclose.

N Joseph Espat, MD, MS, FACS Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center

N Joseph Espat, MD, MS, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Parenteral and Enteral Nutrition, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Central Surgical Association, Chicago Medical Society, International Hepato-Pancreato-Biliary Association, Pancreas Club, Sigma Xi, The Scientific Research Honor Society, Society for Leukocyte Biology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Surgical Oncology, Society of University Surgeons, Southeastern Surgical Congress, Southern Medical Association, Surgical Infection Society

Disclosure: Nothing to disclose.

Mary Denshaw-Burke, MD, FACP Clinical Assistant Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Clinical Assistant Professor, Affiliated Clinical Faculty of the Lankenau Institute for Medical Research; Program Director of Hematology/Oncology Fellowship, Education Coordinator for Oncology, Lankenau Medical Center

Mary Denshaw-Burke, MD, FACP is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article